This virtual symposium is sponsored by Boehringer Ingelheim; product-related information will be discussed.
This promotional video presentation was originally broadcast on 5 May 2021.
Please note that the speaker(s) are not able to answer questions from attendees watching the video on-demand.
Boehringer Ingelheim – a different kind of pharmaceutical company
Family-owned. Purpose-led. Innovation-driven: We serve mankind by improving health for people and animals.
Boehringer Ingelheim was first established in Germany in 1885 and is now one of the top 20 pharmaceutical companies in the world. To this day we remain family-owned, meaning we have the freedom to pursue our purpose – identifying health challenges of the future, and targeting areas of unmet need.
In human pharma, we do this through scientific innovation – taking on the biggest challenges in medicine. We invest in sustainable healthcare – planning for the long term alongside the NHS and our partners in the veterinary world. And we are driving digital transformation by investing in technology to accelerate healthcare improvements.
Pradaxa (150mg and 110mg hard capsules) is indicated for the prevention of stroke an systemic embolism in adult patients with non-valvular AF, with one or more risk factors, such as prior stroke or transient ischemic attack (TIA); age >75 years; heart failure (NYHA Class >II); diabetes mellitus; hypertension.
Praxbind® (idarucizumab) is a specific reversal agent for dabigatran and is indicated in adult patients treated with Pradaxa® (dabigatran etexilate) when rapid reversal of its anticoagulant effects is required: for emergency surgery/urgent procedures; in life-threatening or uncontrolled bleeding.
For more information or to access the current prescriber guide or guide and Summary of Product Characteristics, please visit www.medicines.org.uk/emc
Job code: PC-GB-104029 | Date of prep: May 2021